Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-((1r)-1-((6-amino-5-chloropyrimidine-4-carbonyl)amino)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)-1,3-thiazole-5-carboxamide
2. Mln 2480
3. Mln2480
4. Tak-580
1. 1096708-71-2
2. Mln2480
3. Biib-024
4. Tak-580
5. Mln 2480
6. Mln-2480
7. Biib024
8. Tovorafenib
9. Biib 024
10. Day101
11. Tovorafenib [usan]
12. Tak-580 (mln2480)
13. Tak 580
14. Amg 2112819
15. Tak580
16. Zn90e4027m
17. 2-[(1r)-1-[(6-amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-n-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
18. 6-amino-5-chloro-n-((1r)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-4-pyrimidinecarboxamide
19. 6-amino-5-chloro-n-[(1r)-1-(5-{[5-chloro-4-(trifluoromethyl)pyridin-2-yl]carbamoyl}-1,3-thiazol-2-yl)ethyl]pyrimidine-4-carboxamide
20. 4-pyrimidinecarboxamide, 6-amino-5-chloro-n-[(1r)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-
21. Unii-zn90e4027m
22. 4-pyrimidinecarboxamide, 6-amino-5-chloro-n-((1r)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-
23. 6-amino-5-chloro-n-[(1r)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-4-pyrimidinecarboxamide
24. Qop
25. Tovorafenib [inn]
26. Gtpl9977
27. Schembl4206123
28. Chembl3348923
29. Tak 580 [who-dd]
30. Day-101
31. Dtxsid70149011
32. Ex-a940
33. Chebi:167672
34. 4-pyrimidinecarboxamide, 6-amino-5-chloro-n-((1r)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-
35. Bcp13797
36. Mfcd22571730
37. Nsc766906
38. Nsc800798
39. S7121
40. Who 11985
41. Zinc43202464
42. Mln 2480(biib-024)
43. Akos027323782
44. Amg2112819
45. Ccg-269746
46. Cs-0751
47. Db15266
48. Nsc-766906
49. Nsc-800798
50. Amg-2112819
51. Ncgc00346458-01
52. Ncgc00346458-02
53. Example 10da [us20090036419]
54. Hy-15246
55. P13369
56. J-690031
57. Q27295775
58. (2z,3z)-bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile - Ethanol (1:1)
| Molecular Weight | 506.3 g/mol |
|---|---|
| Molecular Formula | C17H12Cl2F3N7O2S |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 5 |
| Exact Mass | 505.0102337 g/mol |
| Monoisotopic Mass | 505.0102337 g/mol |
| Topological Polar Surface Area | 164 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 695 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
Chongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
Chongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.
About the Company : Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosyn...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
The private placement proceeds will fund the clinical development of the late-stage product Ojemda (tovorafenib) for treating RAF-mutated Pediatric Low-Grade Glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Fairmount
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 30, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Fairmount
Deal Size : $175.0 million
Deal Type : Private Placement
Day One Announces Oversubscribed $175.0 Million Private Placement
Details : The private placement proceeds will fund the clinical development of the late-stage product Ojemda (tovorafenib) for treating RAF-mutated Pediatric Low-Grade Glioma.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 30, 2024
Details:
The agreement aims to commercialize Ojemda (tovorafenib), an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma, the most common form of childhood brain cancer outside the US.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: DiscoveryProduct Type: Small molecule
Sponsor: Ipsen
Deal Size: $461.0 million Upfront Cash: $111.0 million
Deal Type: Licensing Agreement July 25, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Ipsen
Deal Size : $461.0 million
Deal Type : Licensing Agreement
Ipsen and Day One Announce Exclusive Ex-U.S. Licensing Agreement for Tovorafenib
Details : The agreement aims to commercialize Ojemda (tovorafenib), an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma, the most common form of childhood brain cancer outside the US.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : $111.0 million
July 25, 2024
Details:
XOMA acquired potential milestones associated with Ojemda (tovorafenib), approved for patients 6 months age and older with relapsed or refractory pediatric low-grade glioma with BRAF V600 mutation.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Viracta Therapeutics
Deal Size: $108.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 12, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Viracta Therapeutics
Deal Size : $108.0 million
Deal Type : Agreement
XOMA Receives $8.1 Million Milestone for Day One Biopharmaceuticals’ Priority Voucher
Details : XOMA acquired potential milestones associated with Ojemda (tovorafenib), approved for patients 6 months age and older with relapsed or refractory pediatric low-grade glioma with BRAF V600 mutation.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 12, 2024
Details:
Day One sold its rare pediatric disease PRV for FDA approved Ojemda (tovorafenib). It is indicated for the treatment of relapsed/refractory BRAF-mutated glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $108.0 million Upfront Cash: Undisclosed
Deal Type: Divestment May 30, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $108.0 million
Deal Type : Divestment
Day One Announces Sale of Priority Review Voucher for $108 Million
Details : Day One sold its rare pediatric disease PRV for FDA approved Ojemda (tovorafenib). It is indicated for the treatment of relapsed/refractory BRAF-mutated glioma.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 30, 2024
Details:
Onco360 is being selected as a pharmacy partner by Day One Biopharmaceuticals for Ojemda, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Onco360
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 20, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Onco360
Deal Size : Undisclosed
Deal Type : Partnership
BrightSpring Health Announces Onco360 was Selected as National Pharmacy Partner for OJEMDA
Details : Onco360 is being selected as a pharmacy partner by Day One Biopharmaceuticals for Ojemda, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 20, 2024
Details:
XOMA acquired mid-single digit royalties related to Ojemda (tovorafenib), approved for treating patients aged 6 months and older with r/r pediatric low-grade glioma harboring BRAF V600 mutation.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Day One Biopharmaceuticals
Deal Size: $54.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 25, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Day One Biopharmaceuticals
Deal Size : $54.0 million
Deal Type : Agreement
XOMA Earns $9 Million Milestone As FDA Approves OJEMDATM for pLGG
Details : XOMA acquired mid-single digit royalties related to Ojemda (tovorafenib), approved for treating patients aged 6 months and older with r/r pediatric low-grade glioma harboring BRAF V600 mutation.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 25, 2024
Details:
Ojemda (tovorafenib), a type II RAF inhibitor, is approved for relapsed or refractory braf-altered pediatric low-grade glioma (pLGG) in patients 6 months and older.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: Ojemda
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Day One’s OJEMDA Receives FDA Accelerated Approval for Pediatric Glioma
Details : Ojemda (tovorafenib), a type II RAF inhibitor, is approved for relapsed or refractory braf-altered pediatric low-grade glioma (pLGG) in patients 6 months and older.
Brand Name : Ojemda
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2024
Details:
Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatric low-grade glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: DAY101
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Day One Biopharmaceuticals
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 31, 2023
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Day One Biopharmaceuticals
Deal Size : $59.0 million
Deal Type : Agreement
Details : Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatr...
Brand Name : DAY101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 31, 2023
Details:
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in relapsed or progressive pediatric low-grade glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: DAY101
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in relapsed or progressive pediatric low-grade...
Brand Name : DAY101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Details:
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of solid tumors.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Brand Name: DAY101
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of...
Brand Name : DAY101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2035-06-23
US Patent Number : 10426782
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217700
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-06-23
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2031-08-04
US Patent Number : 8293752
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 218033
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-08-04
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2031-08-04
US Patent Number : 8293752
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217700
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-08-04
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2035-06-23
US Patent Number : 10426782
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 218033
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-06-23
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
